Denosumab
Mechanism :
Denosumab is a monoclonal antibody with affinity for nuclear factor-kappa ligand (RANKL).
Indication :
- Hypercalcemia of malignancy
- Glucocorticoid- induced osteoporosis
- Bone metastases from solid tumors
- Giant cell tumor of bone
- Osteoporosis/bone loss
- Multiple myeloma
Contraindications :
Hypersensitivity (systemic) to denosumab or any component of the formulation; pre-existing hypocalcemia; pregnancy.
Dosing :
13 to 17 years:
Giant cell tumor of bone:
SC: 120 mg once every 4 weeks; during the first month, give an additional 120 mg on days 8 and 15.
Adverse Effect :
Peripheral edema, hypertension, fatigue, headache, skin rash, dermatitis, eczema, hypophosphatemia, hypocalcemia, diarrhea, nausea, constipation, anemia, thrombocytopenia, weakness, dyspnea, cough.
Interaction :
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Immunosuppressants: Denosumab may enhance the adverse/toxic effect of immunosuppressants. Specifically, the risk for serious infections may be increased.
Hepatic Dose :
No dosage adjustments are recommended.